Technology
Kanazawa University research: Scientists discover hidden weaknesses in microtubules stabilized by a cancer drug
Published
12 hours agoon
By
High-speed nanoscale imaging reveals how tiny structural defects can cause microtubules to collapse, even when stabilized by the anticancer drug paclitaxel (Taxol).
KANAZAWA, Japan, Oct. 22, 2026 /PRNewswire/ — Researchers at the Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University have discovered that tiny structural defects can trigger the breakdown of microtubules, the microscopic structures that help cells maintain their shape, transport materials and divide. Using high-speed atomic force microscopy, the team observed how these defects develop and sometimes cause microtubules to collapse, even in the presence of paclitaxel, a widely used cancer drug that stabilizes them. The findings, published in ACS Nano, challenge the conventional view that microtubule breakdown begins primarily at their ends and offer new insights into the structural processes that may influence responses to cancer treatment.
Watching the structures that support living cells
Inside almost every cell is a network of microscopic structures known as the cytoskeleton. An important part of this network consists of microtubules, long, hollow tubes assembled from proteins called tubulin. These structures act as internal supports and tracks for transporting materials. They also play an essential role in cell division by helping separate chromosomes into two daughter cells.
Microtubules are constantly changing. They grow by adding tubulin molecules and shrink when these molecules are removed. Sometimes a growing microtubule suddenly begins to shorten rapidly, a process scientists call catastrophe.
For many years, researchers have explained this behavior mainly through changes at the ends of microtubules. In particular, the loss of a stabilizing molecular structure known as the GTP cap can cause the microtubule to begin breaking down.
However, exactly how structural damage develops within the walls of microtubules, and whether such damage can initiate their collapse, has remained difficult to observe directly.
Understanding these processes is particularly important in cancer research. Paclitaxel, also known by the brand name Taxol, is used to treat several types of cancer, including breast and ovarian cancer. It works by stabilizing microtubules and interfering with the changes needed for normal cell division. However, not all cancer cells respond equally to the drug.
Discovering defects inside stabilized microtubules
To investigate how microtubules behave when exposed to paclitaxel, Xin Zhang and colleagues, led by Richard W. Wong at Kanazawa University, used high-speed atomic force microscopy (HS-AFM).
This technique uses an extremely fine probe to scan biological structures in liquid and produce a rapid sequence of images with nanometer-scale detail. Unlike conventional methods that provide static pictures, HS-AFM allows researchers to follow structural changes as they occur.
The team prepared microtubules from purified tubulin proteins, stabilized them with paclitaxel and observed their behavior over time.
At first, many microtubules appeared stable. Their overall tubular shape remained intact, and the researchers could resolve the regularly arranged protein units that make up their walls.
Closer examination, however, revealed something unexpected.
Small defects appeared within otherwise intact regions of the microtubule wall. Some began as shallow depressions only a few nanometers across before gradually developing into larger structural disruptions.
These defects matter because they can weaken the microtubule wall and determine whether the structure remains intact or begins to collapse. Some defects underwent partial repair, while others grew and triggered the breakdown of the microtubule, sometimes spreading in both directions from the damaged region.
Importantly, these changes occurred within the microtubule itself rather than exclusively at its ends, even though the structures had been treated with paclitaxel.
The observations suggest that microtubule stability depends not only on what happens at its ends but also on the condition of the protein framework along its entire length. Tiny structural defects can therefore have consequences for the stability of the whole microtubule.
Four different ways microtubules can collapse
One of the study’s most significant findings was the identification of four distinct patterns of microtubule breakdown.
By analyzing 73 collapse events, the researchers found that 42 percent began at one end of a microtubule, consistent with the conventional model.
However, almost as many events, 40 percent, began at defects within the microtubule wall. In these cases, the structure broke down in both directions from the damaged region.
Another 10 percent of events involved simultaneous breakdown from both ends, while the remaining 8 percent began at multiple sites within the microtubule.
The results show that internal structural defects are a substantial source of microtubule instability under the experimental conditions.
The team also observed temporary structural changes in which parts of the microtubule surface formed curved or arc-like features. Some of these regions underwent further remodeling or partial recovery before either stabilizing or progressing toward collapse.
These observations suggest that microtubule breakdown can develop through a series of structural changes rather than always occurring as a single abrupt event.
Based on these observations, the researchers propose a model called Spontaneous Lattice Decoupling (SLD). The model describes how tiny defects within the microtubule wall can follow two different paths: some undergo repair, allowing the structure to remain intact, while others develop into larger disruptions that eventually cause the microtubule to collapse.
“Microtubules may look stable from the outside, but our observations show that tiny defects can develop within their structure and sometimes lead to complete collapse,” said Richard W. Wong of Kanazawa University’s Nano Life Science Institute. “What is particularly interesting is that these changes can occur even when the microtubules are treated with a drug designed to stabilize them.”
What the findings mean for cancer treatment
Paclitaxel (Taxol) is widely used to treat breast, ovarian, lung and other cancers. It works by stabilizing microtubules and disrupting the structural changes needed for cell division, thereby preventing cancer cells from multiplying.
However, resistance to paclitaxel remains a major clinical challenge. Although several mechanisms of resistance have been identified, the nanoscale structural behavior of microtubules exposed to the drug is not yet fully understood.
The new findings raise an important question: why do microtubules remain vulnerable to structural damage even when treated with a drug designed to stabilize them?
The new findings reveal that paclitaxel-treated microtubules are not necessarily rigid or structurally uniform. Although the drug preserves their overall shape, localized regions can remain vulnerable to structural changes.
This raises the possibility that differences in microtubule structure and the ability to repair or propagate small defects could influence how cells respond to drugs that target microtubules.
The researchers propose a framework in which small structural defects develop, undergo local remodeling, and sometimes progress to microtubule collapse. This sequence provides a way to understand how apparently stable microtubules can still undergo substantial structural changes.
The findings could eventually contribute to research aimed at understanding why some cancer cells respond differently to paclitaxel and related drugs.
However, the present study does not establish a mechanism of drug resistance in cancer cells or demonstrate a new treatment strategy.
The researchers now hope to investigate microtubules associated with cancer cells that are resistant to paclitaxel. By comparing their nanoscale structural behavior with that of microtubules from drug-sensitive cells, they aim to determine whether differences in defect formation, structural stability and repair contribute to resistance. Such studies could provide new insights into why some cancers respond less effectively to microtubule-targeting drugs.
A new view of microtubule stability
Beyond cancer treatment, the findings have implications for understanding the basic biology of microtubules.
These structures are involved in many essential cellular processes, including chromosome separation, intracellular transport and the organization of cell components. Their stability depends on interactions between the individual protein units that form their walls.
The study shows that small local disruptions can have very different outcomes. Some remain temporary and recover, while others spread and lead to the breakdown of an entire microtubule.
The researchers also found that the overall bending of a microtubule was not significantly associated with whether it collapsed. Instead, localized defects appeared to be more closely related to where breakdown began and how it progressed.
By observing these changes directly, the study provides a more detailed picture of how microtubules maintain their structure and how that structure can fail.
Study limitations
The experiments were conducted on microtubules assembled from purified proteins and observed under laboratory conditions rather than inside living cells.
The paclitaxel concentration was selected to provide strong stabilization during prolonged imaging and should not be interpreted as reproducing drug exposure in patients.
Although control experiments showed similar structural changes under different sample preparation conditions, the researchers cannot completely exclude the possibility that interactions between the HS-AFM probe and the microtubules influenced some of the observations
Further studies will be needed to determine how these structural processes occur inside cells and whether they contribute directly to differences in cancer drug sensitivity or resistance.
Figure
https://nanolsi.kanazawa-u.ac.jp/wp/wp-content/uploads/En.png
Figure. Spontaneous Lattice Decoupling (SLD) model of microtubule stability and collapse
Schematic illustration of the Spontaneous Lattice Decoupling (SLD) model proposed from high-speed atomic force microscopy (HS-AFM) observations. Tiny defects in the microtubule wall can follow two different pathways. Some undergo structural repair and regrowth, allowing the microtubule to remain intact. Others develop into larger disruptions that spread through the structure and eventually cause it to collapse. The findings reveal how local structural defects can influence whether a microtubule survives or breaks apart.
Image credit: Xin Zhang. Illustration prepared with the assistance of ChatGPT (OpenAI)
Reference
Xin Zhang, Keesiang Lim, Tomohiro Shima, Elma Sakinatus Sajidah, Masaharu Hazawa, Masahide Kikkawa, Toshio Ando and Richard W. Wong. “Zooming into the Cytoskeleton: Nanodefect-Initiated Microtubule Catastrophe Filmed by High-Speed Atomic Force Microscopy.” ACS Nano (2026).
DOI: 10.1021/acsnano.6c07269
URL: https://doi.org/10.1021/acsnano.6c07269
Funding
This research was supported by MEXT/JSPS KAKENHI grants JP24K18449, JP22H05537, JP22H02209, JP23H04278, JP24H01276, JP25H02360, JP26K01637 and JP26K22904; and JPMJSP2135; JST CREST grant JPMJCR22E3; and support from the Takeda Science Foundation and Shimadzu Science Foundation. The research also received support through the World Premier International Research Center Initiative (WPI), Japan.
Acknowledgements
The researchers thank Professor Tomoyuki Tanaka and Dr. Shuyu Li of the University of Dundee for providing GMPCPP-stabilized microtubules, Professor Yu Wu of West China Hospital, Sichuan University, for clinical discussions on leukemia, and Ms. Zeyang Lin for assistance with chemical illustrations and graphical design. They also acknowledge members of the Richard Wong laboratory.
Media Contact
Motoko YASUHARA (Ms)
Project Planning and Outreach, NanoLSI Administration Office
Nano Life Science Institute, Kanazawa University
Email: nanokoho@adm.kanazawa-u.ac.jp
Kakuma-machi, Kanazawa 920-1192, Japan
About the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University
The Nano Life Science Institute at Kanazawa University develops advanced nanoprobe technologies to directly image, analyze and manipulate biomolecules in living systems. By exploring previously inaccessible nanoscale phenomena, the institute seeks to uncover fundamental principles of life and disease.
https://nanolsi.kanazawa-u.ac.jp/en/
About the World Premier International Research Center Initiative (WPI)
The WPI program was launched in 2007 by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) to establish globally visible research centers with outstanding research environments and a high degree of autonomy. The program is administered by the Japan Society for the Promotion of Science (JSPS).
https://www.jsps.go.jp/english/e-toplevel/
About Kanazawa University
Founded in 1862 in Ishikawa Prefecture, Kanazawa University is one of Japan’s leading comprehensive national universities. The university promotes interdisciplinary research and international collaboration across science, medicine, engineering, the humanities and social sciences.
https://www.kanazawa-u.ac.jp/en/
View original content:https://www.prnewswire.co.uk/news-releases/kanazawa-university-research-scientists-discover-hidden-weaknesses-in-microtubules-stabilized-by-a-cancer-drug-302916595.html
You may like
Technology
Harlem Children’s Zone Acquires FinTech Platform, Goalsetter, to Accelerate Universal Economic Mobility
Published
37 minutes agoon
October 22, 2026By
Acquisition combines HCZ’s proven model with Goalsetter’s innovative financial education technology to expand access and impact at scale
NEW YORK, Oct. 22, 2026 /PRNewswire/ — Today, Harlem Children’s Zone (HCZ), one of the nation’s leading anti-poverty organizations, announced the acquisition of Goalsetter, a financial technology platform that delivers best-in-class, engaging, technology-enabled learning experiences for people seeking to enhance their financial know-how, capabilities, and confidence.
The acquisition marks a significant step in HCZ’s Wealth Builds–Universal Economic Mobility (WB-UEM) strategy, a national framework designed to help children and families build long-term economic security through cradle-to-career supports, financial education and experiences, and direct access to capital via a Child Capital Stack of asset boosts.
“We know that economic mobility is a two-generation challenge,” says Harlem Children’s Zone CEO Kwame Owusu-Kesse. “With this acquisition, we are solving for a critical component of Universal Economic Mobility by melding a proven financial education platform and HCZ’s decades of experience providing people with the knowledge and tools to build strong futures for themselves and their families. This is more than an investment in financial education. It is an investment in critical national infrastructure for economic mobility.”
Harlem Children’s Zone has decades of experience driving outcomes at scale, beginning as a one-block pilot, expanding to over 100 blocks in Central Harlem, and now working with over 70 communities across the United States. HCZ seeks to use its learnings, decades of experience driving outcomes at scale, and renowned best practices to provide pathways to economic mobility for all of America’s children and families.
“Goalsetter was built on the belief that everyone should have access to the financial knowledge and tools that can shape their future and livelihood,” said Tanya Van Court, Chief FinTech Officer at Harlem Children’s Zone and Founder of Goalsetter. “Joining Harlem Children’s Zone gives us an extraordinary opportunity to build on that work. Together, we can continue enhancing the platform, expand access for learners of all ages and walks of life, and demonstrate what is possible when mission, innovation, and technology come together to serve the most people.”
Goalsetter creates opportunities to deliver high-quality, developmentally appropriate and culturally relevant financial education with extensive reach, including to low-income and rural communities that have historically had limited access to these resources. Its current offerings include Goalsetter Classroom, which provides standards-aligned financial education curriculum for middle and high school students, and MoneyLingo, a mobile-first financial education experience for college-aged students and adults in the workforce, covering practical topics such as saving, investing, credit, debt, and financial decision-making.
“This acquisition sends an important signal to the field,” said Owusu-Kesse. “Social impact organizations should not have to choose between mission and scale. By bringing a proven technology platform into HCZ, we’re demonstrating how non-profit organizations can be centers of business excellence, using vehicles of innovation, AI, and technology to create efficient and effective pathways to scale and impact. This acquisition strengthens our in-house capacity to build, innovate, and continuously improve outcomes.”
The organization plans to build upon Goalsetter’s existing offerings by exploring financial education products for younger learners and creating opportunities to establish a continuous financial learning journey from early childhood through adulthood.
“This is ultimately about extending opportunity to all,” added Owusu-Kesse. “By connecting financial education, technology, family engagement, and access to assets, we can help create more accessible pathways to economic mobility.”
Services to current Goalsetter clients will be unaffected by this acquisition.
View original content:https://www.prnewswire.com/news-releases/harlem-childrens-zone-acquires-fintech-platform-goalsetter-to-accelerate-universal-economic-mobility-302917320.html
SOURCE Harlem Children’s Zone
Technology
Common Ground in the Battlegrounds? Surveys Reveal Widespread Bipartisan Agreement in 11 Competitive States and 28 Congressional Districts, as Well as Nationally
Published
37 minutes agoon
October 22, 2026By
Bipartisan Majorities Say If Congress Were to Listen to the People More, They Would More Likely Find Common Ground
COLLEGE PARK, Md., Oct. 22, 2026 /PRNewswire/ — The Program for Public Consultation (PPC) conducted extensive surveys in competitive states and congressional districts, as well as nationally, revealing a remarkable level of bipartisan common ground.
Majorities of both Democrats and Republicans agreed on:
106 policies nationally 82 policies in all states and districts surveyed101 policies in at least two-thirds of all the states and districts surveyed
Over 40,000 Americans were surveyed in two waves with representative samples of 600-2,016 in each of the 11 competitive states surveyed, and 400-592 in each of the 28 competitive congressional districts surveyed, and 1,200-2,509 nationwide.
Nearly all policy questions were based on congressional legislation or executive branch proposals.
Fourteen policy topics were covered: Artificial Intelligence, Housing, Healthcare, Low-Income Assistance, Families and Children, Social Security, Immigration, Abortion and Birth Control, Energy and Environment, Federal Taxes, Campaign Finance, Government Reform, Criminal Justice and America’s Role in the World. For every topic, most policies had bipartisan agreement across every battleground surveyed.
The policy questions used in these national and battleground surveys were chosen because they elicited bipartisan support in previous in-depth national surveys conducted by PPC, in which respondents received briefings on the topic and evaluated pro and con arguments for the proposed policy.
Steven Kull, director of PPC, comments, “What is striking here is that these surveys revealed widespread bipartisan agreement on over a dozen key issues that Congress has failed to resolve, from costs of healthcare, to risks of artificial intelligence, to Social Security’s impending insolvency, and many more. Clearly, there is far more common ground among the American people than there is in Congress.”
Americans Think Public Opinion Should Have More Influence
Respondents were also asked about the role of public opinion in policymaking. Across the battlegrounds, on average, respondents estimated that federally elected officials make the same decisions that the majority of Americans would make just 35% of the time.
Large majorities believe polarization in government comes not from the American people but from elected officials, and that more influence for the people would help break the logjam in Congress (Democrats 62 to 88%, Republicans 66 to 89%).
Perhaps most germane, overwhelming majorities of Democrats and Republicans in the battlegrounds believe that if members of Congress were more influenced by the people, they would be more likely to find common ground (Democrats 82 to 97%, Republicans 80 to 95%), and better serve the common good (Democrats 77 to 94%, Republicans 79 to 94%).
Steven Kull adds, “On the basis of this study, it does appear that the public is correct that if the people had more influence, Congress would be more likely to find common ground, and thus function better.”
Americans also say that public opinion should play a substantial role in news reporting about policy. Over two-thirds say news reports on policy matters should include public opinion data most of the time or always when reliable information is available (Democrats 71 to 88%, Republicans 67 to 89%). Similarly, when Congress is about to vote on a law, large numbers say it is very or extremely important for news outlets to report whether a majority of Americans favor or oppose it (Democrats 65 to 84%, Republicans 60 to 85%).
MORE INFORMATION
Battlegrounds Common Ground SheetIndividual State and District Results, Questionnaires and MethodologiesNational Questionnaire with Toplines, Crosstabs and Methodology
About the Surveys
The state and district surveys used for this analysis were fielded July 21 – August 17, 2026, to a total of 19,949 adults, and May 27 – July 1, 2026, to 19,564 adults. They included 600-2016 in each of the 11 states, and 400-592 in each of the 28 congressional districts. Response rates ranged from 7.1 to 9.0%. Confidence intervals range from +/- 2.9 to 8.1%, and maximum weights range from 1.9 to 10.0.
The national surveys were fielded February 11-26, 2026, with 2,509 adults, and March 11-19, 2026, with 1,200 adults. The response rates were 7.6% and 8.3%, respectively. The confidence interval is +/- 2.9% for both surveys, and the maximum weights are 2.5 and 1.9.
The sample was obtained from multiple online opt-in panels, including Cint, Dynata and Prodege. Sample collection and quality control were managed by QuantifyAI under the direction of the Program for Public Consultation. The surveys were offered in both English and Spanish.
The samples were pre-stratified and weighted by age, race, ethnicity, gender, education, household income, marital status, and home ownership to match the general adult population. The national sample was further weighted by Census region. The distribution of partisan affiliation was within expectations, based on voter registration data for non-leaners and/or Cook’s Partisan Voting Index for leaners, or weighted to reflect those benchmarks.
About the Common Ground in the Battlegrounds? Survey Series
This effort aims to identify bipartisan common ground in competitive states and districts across the nation. The project seeks to educate the public, policymakers and candidates about the findings; and provide journalists with independent, nonpartisan research that brings the public into the conversation about public policy.
In addition to PPC, project partners include the Civic Innovation Center at the University of Maryland (CivIC) and Voice of the People (VOP), a national nonpartisan organization seeking to give the public a greater voice in government. None of these entities advocate for policy positions or endorse candidates.
States surveyed: Alaska; Georgia; Iowa; Maine; Michigan; Minnesota; Montana; Nebraska; New Hampshire; North Carolina; Ohio; and Texas.
Congressional Districts surveyed: Arizona’s 1st and 6th; Colorado’s 8th; Iowa’s 1st, 2nd, 3rd and 4th; Maine’s 2nd; Michigan’s 4th, 7th, 8th and 10th; Montana’s 1st; Nebraska’s 2nd; Nevada’s 3rd; New Jersey’s 7th and 9th; New Mexico’s 2nd; New York’s 3rd, 4th, 17th and 19th; Oregon’s 5th; Pennsylvania’s 1st, 7th, 8th and 10th; and Washington’s 3rd.
The survey series excluded several competitive districts because they were in states that had recently been redistricted and thus had no Census data yet to use for demographic benchmarks.
Program for Public Consultation
The Program for Public Consultation (PPC), affiliated with the University of Maryland’s School of Public Policy, seeks to improve democratic governance by consulting the public and bringing the people’s views into the public discourse. It conducts surveys with representative samples on policies proposed by elected officials and shares its findings with government officials, the media, other academics, and the general public.
Civic Innovation Center
The Civic Innovation Center (CivIC) at the University of Maryland’s School of Public Policy works to strengthen the foundations of civic health. It contributes to important debates about civic education, civic engagement, and needed democratic reforms in the state of Maryland and nationwide, in partnership with other BIG 10 universities. It works to build the connective tissue that brings together students, scholars and practitioners to help elevate the UMD community’s contribution to our wider democracy.
Voice of the People
Voice of the People (VOP) is a nonpartisan organization working to re-anchor our democracy in its founding principles by giving ‘We the People’ a greater and more effective voice in government. It champions innovative methods and technology that enable the American people to play a role in the policymaking process and provide policymakers with a more accurate understanding of the views of their constituents.
Contact: Jonathan Casaverde, jonathan.casaverde@wardcirclestrategies.com,(786) 469-9422
View original content to download multimedia:https://www.prnewswire.com/news-releases/common-ground-in-the-battlegrounds-surveys-reveal-widespread-bipartisan-agreement-in-11-competitive-states-and-28-congressional-districts-as-well-as-nationally-302915872.html
SOURCE Program for Public Consultation
Technology
FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA’s Accuro XV platform
Published
37 minutes agoon
October 22, 2026By
Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmap
CHARLOTTESVILLE, Va., Oct. 22, 2026 /PRNewswire/ — RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for BoneEnhance®, a machine learning software module for the Accuro® XV diagnostic ultrasound system. The module segments bone and surrounding tissues and supports visualization of skeletal anatomy in three dimensions during image review.
The clearance moves the platform from acquisition toward interpretation. Accuro XV was cleared in April 2026 for B-mode imaging in musculoskeletal conventional and superficial applications. Its conformable three-dimensional probe automates large field-of-view image acquisition after initial patient positioning. BoneEnhance is the first machine learning software module cleared for the platform.
BoneEnhance identifies bone and surrounding tissues
Each automated acquisition creates a volumetric dataset for review. BoneEnhance identifies bone and surrounding tissues within that volume, then highlights them with color-coded overlays on the two-dimensional B-mode image. The original anatomical data remain unaltered and visible beneath the overlays. A three-dimensional indicator beside the image shows the scan orientation and the location of the displayed slice within the volume.
A platform milestone
The sequence is deliberate: decision support begins at acquisition. Accuro XV acquires the image; BoneEnhance identifies and labels the anatomy within it. Behind the integrated workflow stands a worldwide intellectual-property portfolio of more than 100 issued and pending patents across more than 20 patent families.
“We founded RIVANNA to solve a problem that cuts across care settings: decision-critical information sits outside the point-of-care workflow,” said Will Mauldin, PhD, Co-founder and CEO of RIVANNA. “BoneEnhance is where the stack begins to close that gap for musculoskeletal care: automated volumetric acquisition, now paired with cleared software-assisted review. This clearance is the foundation: the first machine learning layer, anchoring the decision-support capabilities now in development.”
Independently validated within a nationwide eight-site study
BoneEnhance was trained and validated within RIVANNA’s nationwide eight-site clinical study. Three sites contributed the training data; the other five provided the independent test set of 233 volumetric datasets, comprising 69,900 images from 173 subjects. None of the test data were used for training or tuning. Three board-certified radiologists established the reference labels, and per-volume label prediction accuracy, a measure of anatomical labeling, ranged from 95.1% to 100.0%.
Separate from the validation supporting this clearance, the platform’s automated acquisition carries peer-reviewed evidence: in a published study of 205 patients in the Journal of Emergency Medicine (DOI: 10.1016/j.jemermed.2025.11.011), operators with one hour of hands-on training acquired wrist and ankle images rated adequate for diagnostic interpretation in more than 90% of scans, with image quality comparable to physician-acquired scans.
“This clearance reflects the strength of the team RIVANNA has built across AI development, clinical affairs, and regulatory execution, and the commitment of the clinical sites that partnered with us to generate the evidence,” said Delphine Le Roux, PhD, PMP, Senior Director, Market Access and Strategic Partnerships at RIVANNA. “None of it happens without BARDA’s sustained support, which allowed us to do this the right way: rigorous, multi-site, and independent. The infrastructure, partnerships, and regulatory playbook we established for BoneEnhance are designed to carry forward. That execution engine is what positions us to pursue the next clearance with confidence.”
The next layer in development
The platform’s progression continues with an investigational musculoskeletal injury detection module. Where BoneEnhance labels the anatomy, the new module is being developed to assist clinicians in evaluating potential extremity fractures within acquired ultrasound images. The nationwide clinical study that trained and validated BoneEnhance, now expanded from eight to ten sites, is building the datasets used to train the module. Because the sites and data infrastructure were established once and are reused for each new module, every subsequent module builds on the program’s federal investment.
Federal funding acknowledgment
This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50121C00035.
About Accuro XV
Accuro XV is a portable, small-footprint point-of-care volumetric ultrasound imaging system for musculoskeletal imaging. Its conformable three-dimensional probe automates large field-of-view B-mode image acquisition without ionizing radiation. BoneEnhance is a cleared machine learning software module available during review of Accuro XV volumetric image acquisitions. It segments bone and surrounding tissues and supports visualization of skeletal anatomy in three dimensions.
An investigational computer-aided musculoskeletal injury detection module is in development for Accuro XV. It is designed to assist clinicians in detecting extremity fractures from volumetric ultrasound and annotating soft-tissue signs associated with injury, and to support triage decisions, including referral for additional radiographic imaging.
Accuro XV is designed to provide a fracture-care layer at the point of triage, helping to streamline emergency department workflows, expedite evaluation of low-severity extremity injuries, and reduce reliance on X-ray referrals. The platform is designed to support just-in-time training to promote consistent use across clinical experience levels, advancing a shared mission to transform musculoskeletal injury care while supporting broader emergency preparedness objectives.
About RIVANNA
RIVANNA is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company’s platform is designed to automate complex anatomical analysis at the point of care, support faster and more confident clinical decisions, reduce variability, and expand access to advanced capabilities. Its initial applications address interventional guidance and trauma triage, beginning with neuraxial procedures and musculoskeletal injury assessment. RIVANNA has established an FDA-cleared product portfolio and maintains a worldwide intellectual-property portfolio of more than 100 issued and pending patents. RIVANNA is headquartered in Charlottesville, Virginia, and operates an FDA-registered, ISO 13485:2016-certified manufacturing facility.
RIVANNA, Accuro, BoneEnhance, and the Rivanna Medical family of marks are registered and unregistered trademarks of Rivanna Medical, Inc. in the United States and other jurisdictions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-grants-510k-clearance-for-boneenhance-the-first-machine-learning-layer-on-rivannas-accuro-xv-platform-302917179.html
SOURCE RIVANNA
Harlem Children’s Zone Acquires FinTech Platform, Goalsetter, to Accelerate Universal Economic Mobility
Common Ground in the Battlegrounds? Surveys Reveal Widespread Bipartisan Agreement in 11 Competitive States and 28 Congressional Districts, as Well as Nationally
FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA’s Accuro XV platform
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoBioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar
-
Technology4 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Coin Market3 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks
-
Technology3 days agoInstaMall Launches Same-Day Fashion Delivery Experience, Bringing 80+ Brands to Shoppers’ Doors in Miami
-
Technology4 days agoTruecaller announces preliminary numbers for the third quarter 2026
-
Technology4 days agoSALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
-
Technology4 days agoLinktel Technologies Highlights Breakthrough 1.6T LPO Performance & Strong Market Pull at OCP 2026
-
Technology4 days agoTrend Micro Announces Up to ¥10 Billion toward Cyber Resilience Initiative to Strengthen Security for Japanese Organizations in the AI Era
